Australia will allocate $ 240 million to finance Spinraza treatment for all SMA types under the age of 18

and this is a awesome news for more than 300 families living with SMA in Australia. Health Minister Greg Hunt told the ABC from June 2018, Spinraza will be available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Type 1, Type 2 and Type 3a SMA for all patients under the age of … Fortsätt läsa Australia will allocate $ 240 million to finance Spinraza treatment for all SMA types under the age of 18

Battle to access to Spinraza in Australia – Drug still out of reach for some

I put a directly link to Petition to SMA Australia Spinraza cost over $100.00a a dose Aviana McElwee Story with SMA Type I The Pharmaceutical Benefits Advisory Committee’s decision not to recommend the listing of nusinersen (Spinraza™) on the Pharmaceutical Benefits Scheme in November 2017